News Release

Redirecting cellular protein disposal could open new routes to cancer treatment

Peer-Reviewed Publication

Compuscript Ltd

fig 1

image: 

Image Caption: The domain structure of the VCP hexamer and interacting regions of the VCP N-terminal domain.

view more 

Credit: GAD

 

A review in Genes & Diseases highlights how a protein that helps cells manage unwanted proteins can also support cancer growth. The article places valosin-containing protein, known as VCP or p97, at the center of decisions about which proteins are destroyed, recycled or preserved, revealing potential opportunities for more selective cancer treatments.

 

Prepared by a team at Tulane University School of Medicine, the review examines VCP's role in coordinating two cellular disposal systems: the ubiquitin–proteasome system and autophagy. Together, these systems maintain protein balance, clearing damaged proteins and larger cellular structures that could otherwise disrupt normal function.

 

VCP uses cellular energy to extract and unfold proteins, while partner molecules called cofactors help determine their destination. In cancer, increased VCP levels and changes in these partnerships can redirect protein handling in ways that stabilize cancer-promoting factors or remove proteins that normally restrain tumor growth.

 

The review connects these altered decisions with tumor invasion, metastasis, growth signaling and immune evasion. Its central message is that VCP's effects depend on the proteins it handles, the partners it recruits and its location within the cell.

 

The tumor suppressor p53 illustrates this complexity. VCP can promote the destruction of normal p53, weakening a defense against cancer. Yet it can also stabilize a particular cancer-associated mutant, R273H, helping sustain its harmful activity. These contrasting outcomes suggest that treatment strategies will need to account for a tumor's molecular characteristics.

 

Two regulatory proteins, PLAC8 and SVIP, offer clues. PLAC8 can strengthen VCP interactions linked to protein degradation and cancer-promoting signaling. SVIP can compete with other partners and redirect VCP toward functions associated with lysosomes, the cell's recycling compartments, with predominantly tumor-suppressive effects in the settings described.

 

Potential therapeutic approaches include disrupting selected VCP–cofactor interactions, changing where VCP operates, or shifting protein disposal toward autophagy. However, autophagy can either restrain or support cancer depending on context, making precise control essential.

 

The article also explores the longer-term possibility of recruiting VCP to destroy chosen disease-related proteins. Such targeted degradation could turn cellular machinery into a tool for removing harmful molecular targets.

# # # # # #

Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.

Scopus CiteScore: 10.4 |Impact Factor:14.6

# # # # # #

More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/
All issues and articles in press are available online in ScienceDirect (https://www.sciencedirect.com/journal/genes-and-diseases).

Submissions to Genes & Diseases may be made using Editorial Manager (https://www.editorialmanager.com/gendis/default.aspx).

Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R
Contact Us: editor@genesndiseases.cn
X (formerly twitter): @GenesNDiseases (https://x.com/GenesNDiseases)

# # # # # #

Reference

Charlie J. Hitchman, Julia I. Phillips, Hee-Won Park, Hua Lu, VCP at the crossroads of UPS and autophagy in cancer, Genes & Diseases, Volume 14, Issue 1, 2027, 102264, https://doi.org/10.1016/j.gendis.2026.102264

 

Funding

National Institutes of Health U01CA252964

Ladies Leukemia League Foundation

Krewe de Pink Foundation

Reynolds and Ryan Families Endowed Chair

ACS Discovery Boost grant

Louisiana BOR RSC funds


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.